AI Insight
Researchers at Ikerbasque have developed an iron-based contrast agent for MRI that serves a dual purpose in cardiac fibrosis. The agent selectively accumulates in fibrotic heart tissue, produces stronger MRI signals as disease severity increases, and simultaneously slows the progression of scarring. Testing was conducted on laboratory-grown human heart tissue models.
Why it matters
This theranostic agent could enable earlier detection of heart scarring while providing treatment in the same procedure, potentially improving outcomes for patients with cardiac fibrosis. The dual diagnostic and therapeutic capability may reduce the need for separate interventions and allow for better monitoring of disease progression.
Understand the Science
The Biomolecular Nanotechnology research group led by Ikerbasque research professor Aitziber L. Cortajarena has developed a new iron-based contrast agent for magnetic resonance imaging that can be used for both diagnosis and treatment. In a study carried out on lab-grown human heart tissue, it was proven that the contrast agent accumulates in the fibrotic tissue, that its signal intensity on the MRI image increases with the severity of the disease, and that it slows disease progression.
Source: Iron-based MRI agent detects and slows heart scarring in lab-grown human tissue